<DOC>
	<DOCNO>NCT01632228</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multicenter phase II study evaluate safety efficacy onartuzumab combination bevacizumab compare bevacizumab alone participant recurrent glioblastoma . Participants randomize 1:1 receive either placebo plus bevacizumab every 3 week , onartuzumab plus bevacizumab . Study treatment continue disease progression , unacceptable toxicity , participant physician decision discontinue , death .</brief_summary>
	<brief_title>A Study Onartuzumab ( MetMAb ) Combination With Bevacizumab Compared Bevacizumab Alone Onartuzumab Monotherapy Participants With Recurrent Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm glioblastoma first recurrence concurrent adjuvant chemoradiotherapy Imaging confirmation first tumor progression regrowth define RANO criterion Prior treatment temozolomide No one prior line chemotherapy No prior treatment bevacizumab vascular endothelial growth factor ( VEGF ) VEGFreceptortargeted agent No prior exposure experimental treatment target either hepatocyte growth factor ( HGF ) Met pathway No prior treatment prolifeprospan 20 carmustine wafer No prior intracerebral agent Recovery toxic effect prior therapy No evidence recent hemorrhage baseline magnetic resonance imaging ( MRI ) brain No need urgent palliative intervention primary disease ( e.g . impend herniation ) Karnofsky performance status great equal ( &gt; = ) 70 percent ( % ) Stable decrease dose corticosteroid within 5 day prior randomization Prior therapy gamma knife focal highdose radiotherapy allow , participant must subsequent histologic documentation recurrence , unless recurrence new lesion outside irradiated field Participants undergone recent surgery recurrent progressive tumor eligible provide : surgery must confirm recurrence , minimum 28 day must elapse day surgery randomization core needle biopsy , minimum 7 day must elapse prior randomization , craniotomy intracranial biopsy site must adequately heal free drainage cellulitis , underlie cranioplasty must appear intact time randomization Availability formalin fix paraffin embed tumor tissue representative glioblastoma Pregnant lactate woman Inadequate hematologic , renal liver function History presence serious cardiovascular disease New York Heart Association Grade II great congestive heart failure History another malignancy previous 3 year , except situ cancer basal squamous cell skin cancer Inadequately control hypertension ( define systolic blood pressure great [ &gt; ] 150 millimeter mercury ( mmHg ) and/or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) Prior history hypertensive crisis hypertensive encephalopathy Significant vascular disease ( e.g. , aortic aneurysm require surgical repair recent peripheral arterial thrombosis ) within 6 month prior randomization Evidence bleed diathesis coagulopathy ( absence therapeutic anticoagulation ) Known hypersensitivity excipients onartuzumab bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>